drugset

drugset / Trial / NCT07144020

Donor Derived CD117 CAR-T Cells in the Treatment of R/R Acute Myeloid Leukemia

NCT07144020 ↗

Phase 0 Recruiting 50 enrolled Zhejiang University Yake Biotechnology Ltd. · collab

NaSingle-groupOpen-labelTreatment

Summary

A Clinical Study on the Safety and Effectiveness of Donor Derived CD117 CAR-T Cell in the treatment of Relapsed/Refractory Acute Myeloid Leukemia

Timeline

Start: 2025-09-05
Primary completion: 2028-09-05
Completion: 2028-09-05

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	CD117 CAR T-cells	Cell therapy	—	Intravenous

Indications